OncLive® On Air

Avsnitt

• 
  S19 Ep3: FDA Approval Insights: Ropeginterferon Alfa-2b Ushers in Long-Awaited New Treatment Option for Essential Thrombocythemia 02.10.2026 13min

  In today’s episode, we welcomed Ruben Mesa, MD, FACP, who outlined the significance of the August 2026 FDA approval of ropeginterferon alfa-2b-njft (Besremi) for the treatment of adult patients with essential thrombocythemia. Dr Mesa is senior vice president of Atrium Health and president and executive director of the Atrium Health Wake Forest Baptist Comprehensive Cancer Center in Charlotte, North Carolina.In the exclusive interview, Dr Mesa discussed what the FDA approval of ropeginterferon alfa-2b means for the essential thrombocythemia treatment paradigm, detailed the key efficacy and safety findings from the phase 3 SURPASS-ET trial (NCT04285086) that supported the approval, and looked ahead to other research that could continue to affect this space.
• 
  S19 Ep2: FDA Approval Insights: Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma 30.09.2026 12min

  Dr Reiss Binder discusses the significance of the FDA approval of daraxonrasib for pretreated metastatic pancreatic adenocarcinoma.
• 
  S19 Ep2: Resistance Patterns Shape FGFR Inhibitor Sequencing in Cholangiocarcinoma 30.09.2026 16min

  Dr Vogel highlights the rationale and growing evidence for sequential FGFR inhibition in FGFR2 fusion–positive cholangiocarcinoma.
• 
  S19 Ep1: Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma 30.09.2026 14min

  In this episode, produced in coordination with Oncology Nursing News®, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discussed evolving administration strategies for multiple myeloma therapies, primarily focusing on subcutaneous and on-body administration. Dr Faiman is an adult nurse practitioner in the Department of Hematology/Oncology at the Cleveland Clinic and a clinical member of the Cancer Prevention, Control and Population Research Program at Case Comprehensive Cancer Center in Ohio. Dr Ailawadhi is a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, a consultant in the Department of Cancer Biology, and a professor of medicine at Mayo Clinic in Rochester, Minnesota.In the first episode of a 3-part series, Drs Faiman and Ailawadhi outlined the transition to subcutaneous administration of anti-CD38 monoclonal antibodies in multiple myeloma management. They also highlighted the significance of the July 2026 FDA approval of satuximab-irfc (Sarclisa Escena) for subcutaneous injection for multiple myeloma indications, which includes administration with the CirCLIQ on-body delivery system. 
• 
  S18 Ep50: Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape 30.09.2026 17min

  Drs Cooper and Choudhury discuss the evolving role of DLL3-targeting T-cell engagers in SCLC, with a focus on tarlatamab-dlle (Imdelltra) and how emerging trial data may reshape the current treatment paradigm across lines of therapy.
• 
  S18 Ep49: Start Earlier and Find Your Community: Navigating the Fellowship-to-Faculty Transition Through Mentorship and Specialty-Focused Meetings 30.09.2026 24min

  Drs Aredo and Bleiberg reflect on the experiences and relationships that shaped their transitions from fellowship into their first faculty positions in thoracic oncology and on the role that smaller, specialty-focused meetings played in building the professional community that supported them along the way.
• 
  S18 Ep48: OncoBytes Adaptive Learning Pathways™: Decoding Precision Diagnostics and Targeted Therapies in Glioma 30.09.2026 29min

  Highlights from the PER® CME activity "OncoBytes Adaptive Learning Pathways™: Decoding Precision Diagnostics and Targeted Therapies in Glioma" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Vinay K. Puduvalli, MD; Ruham Nasany, MD; and Angela Waanders, MD, MPH, MS; discuss advances in molecular diagnostics and strategies to treat adults with low- and high-grade gliomas.Earn CME credit by completing the full accredited activity (available through September 1, 2027): https://www.gotoper.com/courses/oncobytes-adaptive-learning-pathways-decoding-precision-diagnostics-and-targeted-therapies-in-gliomaThis podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.
• 
  S18 Ep47: Dissecting Diagnostic and Management Factors in Systemic Mastocytosis 29.09.2026 22min

  In today’s episode, we welcomed Tracy I. George, MD, who provided a pathologist’s perspective on the diagnosis and evolving management considerations for systemic mastocytosis. Dr George is president of the Innovation Business Unit and chief scientific officer at ARUP Laboratories and a professor of pathology at the Spencer Fox Eccles School of Medicine at the University of Utah in Salt Lake City.In the exclusive interview, Dr George highlighted the key hallmarks of systemic mastocytosis that can inform diagnosis, detailed how pathologists collaborate with other multidisciplinary experts to care for patients with systemic mastocytosis, and explained how agents such as avapritinib (Ayvakit) and bezuclastinib (CGT9486) are transforming patient care.
• 
  S18 Ep46: Unpacking Data and Upcoming Developments for Olverembatinib in CML 29.09.2026 11min

  Elias Jabbour, MD, and Dennis Kim, MD, discuss recent data for olverembatininb and its place in CML management.
• 
  S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice 28.09.2026 40min

  Highlights from the PER® CME activity "Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Joyce O’Shaughnessy, MD, Sarat Chandarlapaty, MD, PhD, Mitchell Elliott, MD, FRCPC, and Seth A. Wander, MD, PhD, discuss how they are integrating recent data from pivotal clinical trials evaluating next-generation oral selective estrogen receptor degraders (SERDs) as well as inhibitors of the PI3K/AKT/mTOR signaling pathway into the management of patients with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC), using a variety challenging clinical scenarios to draw out insights and clinical pearls.Earn CME credit by completing the full accredited activity (available through July 31, 2027): https://www.gotoper.com/courses/advancing-targeted-therapy-in-hrher2-metastatic-breast-cancer-integrating-next-generation-endocrine-and-pam-pathway-strategies-into-practiceThis podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from Lilly; Rigel Pharmaceuticals; and Stemline Therapeutics, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.
• 
  S18 Ep44: Exploring the FDA Approval of Optune Pax and What It Means for Locally Advanced Pancreatic Cancer 28.09.2026 11min

  Philip A. Philip, MD, discusses TTFields in pancreatic cancer and what phase 3 data has shown in locally advanced disease.
• 
  S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management 25.09.2026 45min

  Drs Park and Kasi discuss the rise of neoadjuvant immunotherapy in CRC management, framing how this shift fits into the context of larger paradigm changes.
• 
  S18 Ep42: Breaking Down the FDA Approval of Zanidatamab-Based Regimens in HER2+ Gastric Cancer 24.09.2026 11min

  Nataliya Uboha, MD, PhD, discusses zanidatamab-based regimens, their recent approval, and the HERIZON-GEA-01 trial in gastric cancers.
• 
  S18 Ep41: Recent Data Readouts Help Untangle HER2 Overexpression and Mutation Implications in NSCLC 24.09.2026 19min

  Drs Florez and Riess discuss the distinction between HER2 overexpression and HER2 mutations in non–small cell lung cancer.
• 
  S18 Ep40: INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management 23.09.2026 17min

  Davide Melisi, MD, PhD, discusses INCB161734 and the DAWN-303 trial evaluating the agent in KRAS G12D–mutated metastatic pancreatic ductal adenocarcinoma.
• 
  S18 Ep39: Pancreatic Cancer Experts Map Treatment Sequencing With Liposomal Irinotecan and Beyond 21.09.2026 11min

  Raji Shameem, MD, and Shubham Pant, MD, MBBS, discuss the evolving pancreatic cancer treatment paradigm and novel treatments.
• 
  S18 Ep34: Integrating Precision Pathways in HER2+ Gastroesophageal Adenocarcinoma—Testing, Treatment, and Supportive Care 21.09.2026 22min

  Highlights from the PER® CME activity "SimulatED: Integrating Precision Pathways in HER2+ Gastroesophageal Adenocarcinoma — Testing, Treatment, and Supportive Care" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Geoffrey Y. Ku, MD, and Sunnie Kim, MD, discuss essential biomarker testing for advanced gastroesophageal adenocarcinoma, first-line treatment selection for HER2-positive metastatic disease in light of data from HERIZON-GEA-01 (NCT05152147), management of treatment-related diarrhea and other adverse events, and HER2 retesting at disease progression.Earn CME credit by completing the full accredited activity (available through August 31, 2027): https://www.gotoper.com/courses/simulated-integrating-precision-pathways-in-her2-gastroesophageal-adenocarcinoma-testing-treatment-and-supportive-careThis podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.
• 
  S18 Ep38: Fast-Moving Treatment Advances Shape B-Cell Lymphoma Care 17.09.2026 24min

  Drs Park and Brody highlight the rapidly evolving treatment landscape for B-cell lymphomas, noting advances across frontline and relapsed settings.
• 
  S18 Ep37: Metastatic Non-Small Cell Lung Cancer 2026 UPDATE 14.09.2026 13min

  Drs Armstrong and Tawagi deliver a comprehensive, board-focused review of metastatic NSCLC diagnosis and management for 2026.
• 
  S18 Ep36: Precision Immunotherapy, PET-Adapted Regimens, and Novel Targets Are Redefining Hodgkin Lymphoma Care: With Chandler Park, MD; Joshua Brody, MD 14.09.2026 28min

  Drs Park and Brody discuss the evolving frontline and relapsed treatment landscape in Hodgkin lymphoma.